These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Mitochondria: An intriguing target for killing tumour-initiating cells. Yan B; Dong L; Neuzil J Mitochondrion; 2016 Jan; 26():86-93. PubMed ID: 26702582 [TBL] [Abstract][Full Text] [Related]
5. Biology and medicinal chemistry approaches towards various apoptosis inducers. Vyas VK; Chintha C; Pandya MR Anticancer Agents Med Chem; 2013 Mar; 13(3):433-55. PubMed ID: 22721391 [TBL] [Abstract][Full Text] [Related]
6. Modulation of apoptosis to reverse chemoresistance. Mor G; Montagna MK; Alvero AB Methods Mol Biol; 2008; 414():1-12. PubMed ID: 18175807 [TBL] [Abstract][Full Text] [Related]
7. Drug resistance mechanisms in cancer cells: a proteomics perspective. Verrills NM; Kavallaris M Curr Opin Mol Ther; 2003 Jun; 5(3):258-65. PubMed ID: 12870435 [TBL] [Abstract][Full Text] [Related]
8. Apoptotic signaling in multiple myeloma: therapeutic implications. Chauhan D; Hideshima T; Anderson KC Int J Hematol; 2003 Aug; 78(2):114-20. PubMed ID: 12953804 [TBL] [Abstract][Full Text] [Related]
9. Anti-apoptotic mechanisms of drug resistance in cancer. Wilson TR; Johnston PG; Longley DB Curr Cancer Drug Targets; 2009 May; 9(3):307-19. PubMed ID: 19442051 [TBL] [Abstract][Full Text] [Related]
10. Bioenergetic pathways in tumor mitochondria as targets for cancer therapy and the importance of the ROS-induced apoptotic trigger. Ralph SJ; Rodríguez-Enríquez S; Neuzil J; Moreno-Sánchez R Mol Aspects Med; 2010 Feb; 31(1):29-59. PubMed ID: 20026172 [TBL] [Abstract][Full Text] [Related]
11. Apoptotic pathways in tumor progression and therapy. Melet A; Song K; Bucur O; Jagani Z; Grassian AR; Khosravi-Far R Adv Exp Med Biol; 2008; 615():47-79. PubMed ID: 18437891 [TBL] [Abstract][Full Text] [Related]
12. MicroRNA regulation of core apoptosis pathways in cancer. Lima RT; Busacca S; Almeida GM; Gaudino G; Fennell DA; Vasconcelos MH Eur J Cancer; 2011 Jan; 47(2):163-74. PubMed ID: 21145728 [TBL] [Abstract][Full Text] [Related]
13. Defective apoptosis underlies chemoresistance in ovarian cancer. Hajra KM; Tan L; Liu JR Adv Exp Med Biol; 2008; 622():197-208. PubMed ID: 18546629 [No Abstract] [Full Text] [Related]
14. Apoptosis as anticancer mechanism: function and dysfunction of its modulators and targeted therapeutic strategies. Pistritto G; Trisciuoglio D; Ceci C; Garufi A; D'Orazi G Aging (Albany NY); 2016 Apr; 8(4):603-19. PubMed ID: 27019364 [TBL] [Abstract][Full Text] [Related]
15. [Antimitochondrial agents: a new class of anticancer agents]. André N; Rome A; Carré M; Arch Pediatr; 2006 Jan; 13(1):69-75. PubMed ID: 16298120 [TBL] [Abstract][Full Text] [Related]
16. Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Zhang L; Fang B Cancer Gene Ther; 2005 Mar; 12(3):228-37. PubMed ID: 15550937 [TBL] [Abstract][Full Text] [Related]
17. A mitochondrial block and expression of XIAP lead to resistance to TRAIL-induced apoptosis during progression to metastasis of a colon carcinoma. Ndozangue-Touriguine O; Sebbagh M; Mérino D; Micheau O; Bertoglio J; Bréard J Oncogene; 2008 Oct; 27(46):6012-22. PubMed ID: 18560353 [TBL] [Abstract][Full Text] [Related]
18. Apoptosis: future directions in cancer therapy. Ravi D; Panikkar KR; Nair MK; Pillai MR Natl Med J India; 2000; 13(2):71-8. PubMed ID: 10835853 [TBL] [Abstract][Full Text] [Related]
19. Targeting apoptosis for anticancer therapy. Fulda S Semin Cancer Biol; 2015 Apr; 31():84-8. PubMed ID: 24859747 [TBL] [Abstract][Full Text] [Related]
20. Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways. Rohwer N; Cramer T Drug Resist Updat; 2011 Jun; 14(3):191-201. PubMed ID: 21466972 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]